Tags

Type your tag names separated by a space and hit enter

Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Clin Endocrinol (Oxf). 1987 Sep; 27(3):297-306.CE

Abstract

Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h. Subcutaneous injections (33 micrograms) induced impressive suppression of serum GH lasting 3-6 h in eight patients followed by escape to pretreatment values before the next injection. In contrast, continuous infusion resulted in greater and more stable 24 h suppression to the levels reached at the nadir between injections. Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml. In four patients occasional or all levels were above 10 ng/ml (24 h average 12.4-102 ng/ml) implying either that adequate suppression by the SMS 201-995, was impossible during the 3 d pump infusion period, or that the dose administered was inadequate. Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release. Interestingly, and in contrast to somatostatin, SMS 201-995 did not inhibit TSH release. No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged. Fairly constant diurnal serum SMS 201-995 values were obtained during pump infusion, while levels undulated inversely with serum GH during injection treatment. Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 +/- 129 (mean +/- SD) to 385 +/- 100 ng/ml (P less than 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 +/- 76 ng/ml). The normal adult mean is 179 +/- 40 ng/ml. Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week. Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3. The results demonstrate that superior and stable suppression of GH secretion is obtained during continuous s.c. pump infusion of SMS 201-995.

Authors+Show Affiliations

Christensen SE
Second University Clinic of Internal Medicine, Kommunehospitalet, Aarhus, Denmark.
Weeke J
No affiliation info available
Orskov H
No affiliation info available
Møller N
No affiliation info available
Flyvbjerg A
No affiliation info available
Harris AG
No affiliation info available
Lund E
No affiliation info available
Jørgensen J
No affiliation info available

MeSH

AcromegalyAdultAntineoplastic AgentsDrug Administration ScheduleFemaleGrowth HormoneHumansInfusion PumpsInjections, SubcutaneousInsulin-Like Growth Factor IMaleMiddle AgedOctreotideSomatostatin

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2892599

Citation

Christensen, S E., et al. "Continuous Subcutaneous Pump Infusion of Somatostatin Analogue SMS 201-995 Versus Subcutaneous Injection Schedule in Acromegalic Patients." Clinical Endocrinology, vol. 27, no. 3, 1987, pp. 297-306.
Christensen SE, Weeke J, Orskov H, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf). 1987;27(3):297-306.
Christensen, S. E., Weeke, J., Orskov, H., Møller, N., Flyvbjerg, A., Harris, A. G., Lund, E., & Jørgensen, J. (1987). Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clinical Endocrinology, 27(3), 297-306.
Christensen SE, et al. Continuous Subcutaneous Pump Infusion of Somatostatin Analogue SMS 201-995 Versus Subcutaneous Injection Schedule in Acromegalic Patients. Clin Endocrinol (Oxf). 1987;27(3):297-306. PubMed PMID: 2892599.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. AU - Christensen,S E, AU - Weeke,J, AU - Orskov,H, AU - Møller,N, AU - Flyvbjerg,A, AU - Harris,A G, AU - Lund,E, AU - Jørgensen,J, PY - 1987/9/1/pubmed PY - 1987/9/1/medline PY - 1987/9/1/entrez SP - 297 EP - 306 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 27 IS - 3 N2 - Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h. Subcutaneous injections (33 micrograms) induced impressive suppression of serum GH lasting 3-6 h in eight patients followed by escape to pretreatment values before the next injection. In contrast, continuous infusion resulted in greater and more stable 24 h suppression to the levels reached at the nadir between injections. Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml. In four patients occasional or all levels were above 10 ng/ml (24 h average 12.4-102 ng/ml) implying either that adequate suppression by the SMS 201-995, was impossible during the 3 d pump infusion period, or that the dose administered was inadequate. Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release. Interestingly, and in contrast to somatostatin, SMS 201-995 did not inhibit TSH release. No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged. Fairly constant diurnal serum SMS 201-995 values were obtained during pump infusion, while levels undulated inversely with serum GH during injection treatment. Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 +/- 129 (mean +/- SD) to 385 +/- 100 ng/ml (P less than 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 +/- 76 ng/ml). The normal adult mean is 179 +/- 40 ng/ml. Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week. Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3. The results demonstrate that superior and stable suppression of GH secretion is obtained during continuous s.c. pump infusion of SMS 201-995. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/2892599/Continuous_subcutaneous_pump_infusion_of_somatostatin_analogue_SMS_201_995_versus_subcutaneous_injection_schedule_in_acromegalic_patients_ DB - PRIME DP - Unbound Medicine ER -